Point72 Asset Management L.P. acquired a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,782,007 shares of the company's stock, valued at approximately $3,903,000. Point72 Asset Management L.P. owned approximately 2.52% of Ventyx Biosciences as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently bought and sold shares of VTYX. Catalina Capital Group LLC acquired a new position in Ventyx Biosciences during the 4th quarter worth $25,000. AXQ Capital LP acquired a new position in Ventyx Biosciences during the 4th quarter worth $29,000. Palumbo Wealth Management LLC lifted its holdings in Ventyx Biosciences by 97.1% during the 4th quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company's stock worth $52,000 after buying an additional 11,792 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in Ventyx Biosciences by 76.0% during the 4th quarter. MetLife Investment Management LLC now owns 26,731 shares of the company's stock worth $59,000 after buying an additional 11,543 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in Ventyx Biosciences by 23.3% during the 4th quarter. Wells Fargo & Company MN now owns 41,170 shares of the company's stock worth $90,000 after buying an additional 7,768 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company's stock.
Ventyx Biosciences Price Performance
Shares of VTYX stock traded down $0.13 during trading hours on Friday, reaching $1.69. The company had a trading volume of 1,361,034 shares, compared to its average volume of 1,337,950. The company has a 50 day moving average of $1.21 and a 200 day moving average of $1.73. The firm has a market cap of $120.26 million, a price-to-earnings ratio of -0.72 and a beta of 0.73. Ventyx Biosciences, Inc. has a 1-year low of $0.78 and a 1-year high of $5.66.
Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.09. As a group, sell-side analysts forecast that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.
Ventyx Biosciences Company Profile
(
Free Report)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Read More
Before you consider Ventyx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list.
While Ventyx Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
